



Can-Fite BioPharma announces the completion of enrolment of the first 100 patients for it's Psoriasis Phase II/III clinical study with CF101

Petah Tikva, Israel, April 23 2012: Can-Fite BioPharma (TASE: CFBI) announced today the completion of enrolment of the first 100 patients for it's Psoriasis Phase II/III clinical trial with CF101. An interim analysis recommendation by the independent data monitoring committee (DMC) is expected to be released in the third quarter this year.

The Phase II/III trial is a multicenter (US, Europe and Israel), randomized, double-blind, placebo-controlled where patients are randomly assigned to parallel dosing groups of CF101 1 mg, CF101 2 mg, or matching placebo. The primary endpoint of the study is proportion of patients achieving Physician Global Assessment (PGA) of 0 or 1, an endpoint that was found statistically significant in the Phase II psoriasis trial previously conducted by the company.

Psoriasis is a skin condition that affects 2% to 3% of the general population. The Psoriasis therapeutics market is estimated at US\$ 3.5 billion annually and is dominated by biological drugs, which are efficient but are very expensive and has side effects. The oral administration of Can-Fite's CF101, the drug's mechanism of action (suppression of the inflammatory cells while not effecting the healthy cells) and its excellent safety profile (tested on more than 600 subjects), support its use for the treatment of psoriasis. In addition, CF101 is a small molecule with much lower cost of goods than the biological drugs currently available for the treatment of Psoriasis.

Can-Fite CEO Prof. Pnina Fishman commented, "We are very pleased with the recruitment of the first 100 patients for the Phase II/III clinical trial of CF101 for the treatment of psoriasis according to our planed schedule. This advanced global clinical study is performed under an open IND in a large population and I would like to thank the clinical investigators in the various clinical centers. The CF101 drug candidate may assist psoriasis patients which are currently suffering from the various side effects of the drugs on the market. We are looking forward to complete this part of the study and for the release of the DMC recommendation".

About Can-Fite Biopharma Ltd.

Can-Fite Biopharma Ltd is a public company, trading on the Tel Aviv Stock Exchange. The company, which commenced business activity on 2000, was founded by Prof Pnina Fishman, researcher in the Rabin Medical Center, and Dr Ilan Cohen, patent attorney and senior partner at Reinhold Cohen Patent Attorneys. Prof Fishman serves as CEO of the company. The company was founded on the basis of Prof Fishman's scientific findings, and is focused on the development of small molecule drugs, ligands to the A3 adenosine receptor. The latter mediates anti-inflammatory and anti-cancer effects and is suggested as a biological predictive marker. The company's lead drug, CF101, is in advanced clinical development for the treatment of autoimmune inflammatory diseases. The CF102 drug candidate is being developed for the treatment of liver diseases. Can-Fite has a wealth of clinical experience: to date, more than 700 patients have participated in clinical trials conducted by the company. Can-Fite recently licensed its activity in the ophthalmic field to OphthaliX Inc.

Contact:

Pnina Fishman, Chief Executive Officer

Tel: +972-3-9241114

Email: pnina@canfite.com